475 related articles for article (PubMed ID: 10373224)
1. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
2. Candesartan, an Insurmountable Antagonist of Angiotensin II-mediated Contractile Effects in Isolated Vascular Preparations: Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).
Morsing U Brandt-Eliasson L Renberg T Abrahamsson P
Blood Press; 2000; 9(sup1):50-51. PubMed ID: 28425810
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
4. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of dithiothreitol on angiotensin II-induced contractions mediated by AT1-receptors in rat portal vein and rabbit aorta.
Zhang JS; van Meel JC; Pfaffendorf M; van Zwieten PA
Naunyn Schmiedebergs Arch Pharmacol; 1994 May; 349(5):538-42. PubMed ID: 8065468
[TBL] [Abstract][Full Text] [Related]
6. Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
Wagenaar LJ; Voors AA; Buikema H; van Buiten A; Lübeck RH; Boonstra PW; van Veldhuisen DJ; van Gilst WH
Cardiovasc Drugs Ther; 2002 Jul; 16(4):311-6. PubMed ID: 12652100
[TBL] [Abstract][Full Text] [Related]
7. Candesartan Causes Long-lasting Antagonism of the Angiotensin II Receptor-mediated Contractile Effects in Isolated Vascular Preparations: a Comparison with Irbesartan, Losartan and its Active Metabolite (EXP-3174).
Abrahamsson T; Karp L; Brandt-Eliasson U; Morsing P; Renberg L; Sjöquist PO
Blood Press; 2000; 9(sup1):52. PubMed ID: 28425811
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
[TBL] [Abstract][Full Text] [Related]
10. Different types of antagonism by losartan and irbesartan on the effects of angiotensin II and its degradation products in rabbit arteries.
Li Q; Pfaffendorf M; van Zwieten PA
Fundam Clin Pharmacol; 2001 Apr; 15(2):143-50. PubMed ID: 11468024
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
[TBL] [Abstract][Full Text] [Related]
13. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
14. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Mallion JM; Badguet JP
J Hum Hypertens; 2000 Oct; 14 Suppl 2():S33-41. PubMed ID: 11086634
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
16. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
[TBL] [Abstract][Full Text] [Related]
17. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
19. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
Unger T
Am J Cardiol; 1999 Nov; 84(10A):9S-15S. PubMed ID: 10588089
[TBL] [Abstract][Full Text] [Related]
20. Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
Dendorfer A; Dominiak P; Tempel K; Raasch W
J Hypertens; 2005 Oct; 23(10):1861-7. PubMed ID: 16148610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
